Johnson & Johnson (JNJ.HM)

136.44

-0.28

(-0.20%)

As of 10:04:24 AM GMT+2. Market Open.

JNJ vs. ABBV: Which Pharma Powerhouse Has Better Growth Prospects?

Both JNJ and ABBV expect their sales and profits to improve in 2025.

Zacks 1 hour ago

JNJ

ABBV
Johnson & Johnson (NYSE:JNJ) Is Paying Out A Larger Dividend Than Last Year

Johnson & Johnson ( NYSE:JNJ ) will increase its dividend from last year's comparable payment on the 10th of June to...

Simply Wall St. 2 hours ago

JNJ
ChatGPT Stock Advice: Johnson & Johnson (JNJ) Among Top Stock Recommendations

We recently published a list of ChatGPT Stock Advice: Top 12 Stock Recommendations. In this article, we will take a look at where Johnson & Johnson (NYSE:JNJ) stands against other top stock recommendations by ChatGPT. After a two-year surge of 53%, the stock market has been taken for a wild ride in 2025, driven by […]

Insider Monkey 5 hours ago

JNJ
MedTechs Adjust 2025 Outlook Amid Tariffs: What Investors Need to Know

Most of the MedTech players have adjusted their 2025 forecasts in response to rising tariff pressure.

Zacks 19 hours ago

BSX

JNJ
Was Jim Cramer Right About Johnson & Johnson (JNJ)?

We recently published a list of Did Jim Cramer Hit or Miss On These 13 Stock Predictions? In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discussed during the episode of Mad Money on May 1st, 2024. During the Mad Money episode […]

Insider Monkey yesterday

JNJ
TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks

Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ulcerative colitis (UC). The ASTRO Week 24 data build on the Week 12 SC induction data that showed statistically significant and clinically meaningful improvements compared to placebo across all clinical and endoscopic measures consistent with the U.S. Food and Drug Administration (FDA)-approved intra

PR Newswire yesterday

JNJ
TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years

Johnson & Johnson (NYSE: JNJ) today announced new data from the TREMFYA® (guselkumab) Phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC). These data are among 24 abstracts highlighting the Company's research being presented at Digestive Disease Week (DDW) 2025.

PR Newswire yesterday

JNJ
If You Invested $10K In Johnson & Johnson Stock 10 Years Ago, How Much Would You Have Now?

Johnson & Johnson (NYSE:JNJ) engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. If You Bought Johnson & Johnson Stock 10 Years Ago The company's stock traded at approximately $99.20 ...

Benzinga yesterday

JNJ
Is Johnson & Johnson (JNJ) The Most Profitable Cheap Stock to Buy Now?

We recently compiled a list of the 10 Most Profitable Cheap Stocks to Buy Now. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other most profitable cheap stocks to buy. US stocks rose on Friday, May 2, as the S&P 500, Dow Jones Industrial […]

Insider Monkey yesterday

JNJ

^GSPC

^DJI
Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash?

President Trump recently warned big drugmakers that a pharmaceutical "tariff wall" is coming. Investors often view Pharmaceutical stocks as safe havens during periods of market turbulence. Indeed, shares of the three biggest pharmaceutical companies based on market cap -- AbbVie (NYSE: ABBV), Eli Lilly (NYSE: LLY), and Johnson & Johnson (NYSE: JNJ) -- have all delivered solid gains so far this year, while the major market indexes have fallen.

Motley Fool 2 days ago

JNJ

ABBV

LLY
Q1 earnings pulse check: companies tentative on pharma-specific tariffs

Whilst 2025 outlooks include cost impacts from existing tariffs, companies have not adjusted their guidance for future pharma-specific ones.

Pharmaceutical Technology 3 days ago

GLDAF

JNJ
'Declare victory and move on': Eli Lilly CEO on Trump tariff threat

Eli Lilly CEO says Trump tariff threat has already achieved the goal of repatriating manufacturing in pharma.

Yahoo Finance 4 days ago

PFE

JNJ

RHHBF
Pharma downplays tariff threat, even as risks remain unclear

Drugmaker executives have projected confidence they can mitigate the impact of any levies Trump imposes on the industry. Yet they're adjusting inventory and production nonetheless.

BioPharma Dive 5 days ago

JNJ
If A Recession Hits, Will Medical Stocks Be A Safe Haven For Investors — Again?

Medical stocks could see a resurgence if the economy hits a speed bump due to tariffs. But which health care stocks are worth watching?

Investor's Business Daily 5 days ago

LLY

ISRG

JNJ
FDA approves J&J’s Imaavy for generalised myasthenia gravis

The approval by the US regulator is based on data from the pivotal Vivacity-MG3 trial.

Pharmaceutical Technology 5 days ago

JNJ
The Zacks Analyst Blog Highlights Amazon, Johnson & Johnson, Cisco Systems and NeurAxis

Amazon, Johnson & Johnson, Cisco Systems and NeurAxis are included in this Analyst Blog.

Zacks 5 days ago

JNJ

CSCO

AMZN
Trump Says Tariffs Politically Risky, But He’s Not Rushing Deals

President Donald Trump acknowledged that his sweeping tariff program had risked imperiling him politically, but said he would not rush deals to appease nervous investors during a town hall on Wednesday.

Bloomberg 5 days ago

TM

TOYOF

NVDA
Top Stock Reports for Amazon.com, Johnson & Johnson & Cisco Systems

Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Johnson & Johnson (JNJ) and Cisco Systems, Inc. (CSCO), as well as a micro-cap NeurAxis, Inc. (NRXS).

Zacks 5 days ago

JNJ

CSCO

AMZN
Johnson & Johnson (JNJ): Jim Cramer Says “They Love the Weak Dollar” — Is This Quiet Giant Back in Favor?

We recently published a list of Jim Cramer Reveals Details Of Trump’s Tariff Negotiations & Discusses 10 Stocks. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks that Jim Cramer discusses. In his recent appearance on CNBC’s Squawk on the Street, Jim Cramer commented […]

Insider Monkey 5 days ago

JNJ
Is Johnson & Johnson (JNJ) the Best Dow Stock for the Next 12 Months?

We recently published a list of The Best and Worst Dow Stocks for the Next 12 Months. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other best and worst dow stocks for the next 12 months. The Dow Jones Industrial Average (DJIA), or the Dow, […]

Insider Monkey 5 days ago

JNJ

^DJI

Performance Overview

Return	JNJ.HM	S&P 500 (^GSPC)
YTD	-1.45%	-4.64%
1-Year	+1.48%	+8.26%
3-Year	-9.94%	+36.02%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

Johnson & Johnson (JNJ.HM)

JNJ vs. ABBV: Which Pharma Powerhouse Has Better Growth Prospects?

Johnson & Johnson (NYSE:JNJ) Is Paying Out A Larger Dividend Than Last Year

ChatGPT Stock Advice: Johnson & Johnson (JNJ) Among Top Stock Recommendations

MedTechs Adjust 2025 Outlook Amid Tariffs: What Investors Need to Know

Was Jim Cramer Right About Johnson & Johnson (JNJ)?

TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks

TREMFYA® (guselkumab) delivers sustained clinical and endoscopic remission in ulcerative colitis through two years

If You Invested $10K In Johnson & Johnson Stock 10 Years Ago, How Much Would You Have Now?

Is Johnson & Johnson (JNJ) The Most Profitable Cheap Stock to Buy Now?

Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash?

Q1 earnings pulse check: companies tentative on pharma-specific tariffs

'Declare victory and move on': Eli Lilly CEO on Trump tariff threat

Pharma downplays tariff threat, even as risks remain unclear

If A Recession Hits, Will Medical Stocks Be A Safe Haven For Investors — Again?

FDA approves J&J’s Imaavy for generalised myasthenia gravis

The Zacks Analyst Blog Highlights Amazon, Johnson & Johnson, Cisco Systems and NeurAxis

Trump Says Tariffs Politically Risky, But He’s Not Rushing Deals

Top Stock Reports for Amazon.com, Johnson & Johnson & Cisco Systems

Johnson & Johnson (JNJ): Jim Cramer Says “They Love the Weak Dollar” — Is This Quiet Giant Back in Favor?

Is Johnson & Johnson (JNJ) the Best Dow Stock for the Next 12 Months?

Performance Overview